Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

By Dr. Matthew Watson

MARKHAM, Ontario, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Dr. Pardeep Nijhawan (“Dr. Nijhawan”) announces that as a result of grants of restricted share units (“RSUs”) of Edesa Biotech, Inc. (“Edesa”), when combined with a series of transactions (the “Transactions”) that have occurred since the date of the most recent early warning report filed by Dr. Nijhawan on November 18, 2022 (the “Previous Report”), Dr. Nijhawan has acquired “beneficial ownership” of common shares in the capital of Edesa (“Common Shares”) in an amount equal to more than 2% of the issued and outstanding Common Shares since the date of the Previous Report.

Read the rest here:
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

Related Post


categoriaGlobal News Feed commentoComments Off on Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc. | dataSeptember 14th, 2024

About...

This author published 5852 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024